Nephrol Dial Transplant (2003) 18: 362-369
© 2003 European Renal Association-European Dialysis and Transplant Association
Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo)
1 Department of Nephrology and Dialysis, A Manzoni Hospital, Lecco, Italy, 2 Nephrology Department, Hôpital Lapeyronie, Montpellier, 3 Centre Hospitalier Intercommunal, Tarbes, France, 4 Servicio de Nefrologia, Hospital Universitario Reina Sofia, CordobaSpain and 5 Amgen Limited, Cambridge, UK
Background. Darbepoetin alfa is an erythropoietic agent with a 3-fold longer elimination half-life than recombinant human erythropoietin (rHuEpo), which allows less frequent dosing. This study investigated the safety and efficacy of darbepoetin alfa for treating anaemia in dialysis patients, using a dosing regimen that was independent of the patient's body weight (unit dosing).
Methods. Dialysis patients (n=341) maintained on rHuEpo treatment (alfa or beta) were switched to darbepoetin alfa at a reduced dosing frequency, but by the same route of administration [intravenous (i.v.) or subcutaneous (s.c.)]. Patients receiving rHuEpo two or three times weekly changed to once-weekly darbepoetin alfa, and those receiving rHuEpo once weekly changed to once every other week darbepoetin alfa. The unit doses of darbepoetin alfa (10–150 µg) were titrated to maintain haemoglobin concentrations within -1.0 and +1.5 g/dl of the individual mean baseline haemoglobin and between 10 and 13 g/dl for 24 weeks.
Results. Mean change in haemoglobin from baseline to the evaluation period (weeks 21–24) was 0.13 g/dl (95% CI, 0.01, 0.25), which was not clinically relevant. An analysis by route of administration revealed that mean haemoglobin concentrations had increased by 0.58 g/dl (95% CI, 0.33, 0.82) in patients receiving i.v. darbepoetin alfa, and previously treated with i.v. rHuEpo, while remaining unchanged in s.c. patients (0.00 g/dl; 95% CI, -0.13, 0.13) previously treated by s.c. rHuEpo. In addition, there was a statistically significant decrease in mean weekly i.v. darbepoetin alfa dose requirements from 25.2 µg/week at baseline to 21.5 µg/week (P=0.004) during the evaluation period (-17.3%). Subcutaneous weekly dosage requirements increased slightly during the study period (20.8 to 22.7 µg/week; P=0.014). An i.v./s.c. dose ratio of 0.95 (95% CI, 0.78, 1.14) at evaluation confirms previous findings that dose requirements by the i.v. and s.c. routes were not different in patients treated with darbepoetin alfa. Haemoglobin concentrations were also effectively maintained in patients who received darbepoetin alfa once weekly and once every other week. Darbepoetin alfa was well tolerated.
Conclusions. The treatment of renal anaemia in dialysis patients with unit doses of darbepoetin alfa effectively and safely maintains target haemoglobin concentrations with less frequent dosing. Dose requirements for darbepoetin alfa following i.v. and s.c. administration were not different. The results of this study demonstrate that darbepoetin alfa administered i.v. once weekly, or once every other week is an effective treatment regimen for haemodialysis patients with renal anaemia.
Keywords: darbepoetin alfa; dose requirements; intravenous; renal anaemia; subcutaneous; unit dosing
Correspondence and offprint requests to: Professor Francesco Locatelli, A Manzoni Hospital, Department of Nephrology and Dialysis, Via Dell'Eremo 9/11, 23900 Lecco, Italy. Email: nefrologia{at}ospedale.lecco.it
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y.-W. Fang and C.-H. Chang SUBCUTANEOUS ADMINISTRATION OF DARBEPOETIN ALFA EFFECTIVELY MAINTAINS HEMOGLOBIN CONCENTRATIONS AT EXTENDED DOSE INTERVALS IN PERITONEAL DIALYSIS PATIENTS Perit. Dial. Int., March 1, 2009; 29(2): 199 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Carrera and M. Burnier Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations NDT Plus, January 1, 2009; 2(suppl_1): i9 - i17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bommer, G. Asmus, M. Wenning, and G. Bommer A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study Nephrol. Dial. Transplant., December 1, 2008; 23(12): 4002 - 4008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. K. Lee, S. G. Kim, J. W. Seo, J. E. Oh, J.-W. Yoon, J.-R. Koo, H. J. Kim, and J. W. Noh A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study Nephrol. Dial. Transplant., October 1, 2008; 23(10): 3240 - 3246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Bock, P. Hirt-Minkowski, M. Brunisholz, G. Keusch, S. Rey, B. von Albertini, and for the Swiss EFIXNES trial investigators Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta Nephrol. Dial. Transplant., January 1, 2008; 23(1): 301 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. C. Macdougall, D. Padhi, and G. Jang Pharmacology of darbepoetin alfa Nephrol. Dial. Transplant., June 1, 2007; 22(suppl_4): iv2 - iv9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Carrera, A. Disney, and M. Molina Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data Nephrol. Dial. Transplant., June 1, 2007; 22(suppl_4): iv19 - iv30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lucas, F. Carrera, C. Jorge, H. Boquinhas, and M. J. Pais Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients Nephrol. Dial. Transplant., November 1, 2006; 21(11): 3202 - 3206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-D. Tang and S. D. Katz Anemia in Chronic Heart Failure: Prevalence, Etiology, Clinical Correlates, and Treatment Options Circulation, May 23, 2006; 113(20): 2454 - 2461. [Full Text] [PDF]
|
|
|
|
|
|
M. Aarup, J. Bryndum, H. Dieperink, and P. Joffe Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1312 - 1316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Galliford, R. Malasana, and K. Farrington Switching from subcutaneous to intravenous erythropoietin {alpha} in haemodialysis patients requires a major dose increase Nephrol. Dial. Transplant., September 1, 2005; 20(9): 1956 - 1962. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Justice, J. F. Kessler, J. Jadeja, L. Campos, J. Weick, C.-F. Chen, A. C. Heatherington, and R. G. Amado A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia Ann. Onc., July 1, 2005; 16(7): 1192 - 1198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Brunkhorst, J. Bommer, J. Braun, M. Haag-Weber, C. Gill, J. Wagner, and T. Wagener Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients Nephrol. Dial. Transplant., May 1, 2004; 19(5): 1224 - 1230. [Abstract] [Full Text] [PDF]
|
|